Hong Kong Daily Briefing

Hong Kong-listed Akeso (9926.HK) announced the first patient enrolled in its global Phase III trial of cadonilimab versus nivolumab in first-line gastric cancer, per PR Newswire. This is a landmark in China/HK biopharma expansion: Akeso competing head-to-head with Bristol-Myers Squibb's Opdivo on a global Phase III basis signals commercial ambition beyond the China domestic market. For HSCEI-tracking investors, HK biotech is a structural growth story that typically trades at a premium to the HSI's bank-and-property composition — Akeso's trial enrollment is the pipeline catalyst that sustains that premium.

FinanceAsia HK reports Mitsubishi Corporation is expanding its investment stake in Philippine conglomerate Ayala. The deal is relevant for HK/APAC portfolio managers tracking Japanese sogo shosha capital allocation — Mitsubishi and the other Big Five trading houses have been systematically deepening APAC equity exposure under the 'Buffett Japan' dividend reinvestment mandate. For HK as a regional financial hub, Japanese capital recycling through HK-listed vehicles is a Southbound-complementary flow that adds liquidity depth to HKEX.

Clifford Capital (a MAS-backed infrastructure financing platform) closed its ninth Infrastructure Asset-Backed Securities (IABS) issuance with strong demand driven by infrastructure build-out, per FinanceAsia HK. IABS as a product class is significant for HK's role as an infrastructure debt capital market: deals like this price the risk-free alternative for REIT investors and help establish the yield floor for S-REIT distribution yields. With the USD/HKD peg holding and HKMA following Fed rate path, HK infrastructure debt spreads are the cleanest read on regional credit appetite.